Electrophysiologic effects of ethmozin in patients with ventricular tachycardia.

Abstract

Ten patients with recurrent episodes of ventricular tachycardia (VT) had electrophysiologic studies in the basal state and on chronic oral ethmozin (12.1 +/- 0.6 SE mg/kg/day). Ethmozin significantly prolonged the AH interval (basal: 75 +/- 8 SE msec; ethmozin: 91 +/- 10 msec, p less than 0.05), the HV interval (51 +/- 3; 66 +/- 5 msec, p less than 0.01), and the QRS duration (101 +/- 4; 118 +/- 4 msec, p less than 0.001). Atrial and ventricular refractory periods and the corrected QT interval were not significantly affected by ethmozin. VT was induced in 7 of 10 patients in the basal state by means of programmed right ventricular extrastimulation or rapid burst ventricular pacing. On oral ethmozin nine patients had inducible VT. VT cycle length was consistently prolonged on ethmozin (250 +/- 13; 326 +/- 14 msec, p less than 0.001). Four of the seven patients with VT on basal ambulatory monitoring had total abolition of spontaneous VT on ethmozin. Ethmozin failed to prevent induction of VT in most patients despite significant reductions in ventricular arrhythmia on ambulatory monitoring. Further studies comparing VT induction with ambulatory monitoring in patients on ethmozin are needed to confirm these findings and to define the clinical significance of this dissociation.

• Authors: D E Mann, J C Luck, J M Herre, S A Magro, S C Yepsen, J C Griffin, C M Pratt, C R Wyndham
• Journal: American heart journal (Am Heart J) Vol. 107 Issue 4 Pg. 674-9 (Apr 1984) ISSN: 0002-8703 [Print] United States
• PMID: 6367405 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Anti-Arrhythmia Agents
• Phenothiazines
• Moricizine

Topics

• Adult
• Aged
• Anti-Arrhythmia Agents (therapeutic use)
• Cardiac Pacing, Artificial
• Electrocardiography
• Electrophysiology
• Female
• Heart Conduction System (physiopathology)
• Heart Ventricles
• Humans
• Male
• Middle Aged
• Moricizine
• Phenothiazines (therapeutic use)
• Tachycardia (drug therapy, physiopathology)